Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Der CEO kauft ein - und das gleich zweimal: Startschuss für die nächste Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
02.04.25
07:30 Uhr
10,500 Euro
-0,200
-1,87 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,20010,30007:53
10,10010,50007:52

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05:47CCBI Lifts AKESO's TP to $90, Rating Kept Outperform1
AKESO Aktie jetzt für 0€ handeln
05:17HTSC Raises 2025/2026 NP Forecasts for AKESO , Lifts TP to $103.681
DiHSI Closes at 23,206, Up 87 pts; HSTI Closes at 5,407, Up 12 pts; CSPC PHARMA Up over 10%; LAOPU GOLD, CENTRAL NEW EGY, AKESO, ANE, LONKING Hit New Highs; Market Turnover Rises10
DiHSI Up 244 pts; HSTI Up 97 pts; CSPC PHARMA Up over 12%; HANSOH PHARMA, CENTRAL NEW EGY, AKESO, LAOPU GOLD, 3SBIO Hit New Highs6
DiBOCI Lifts AKESO's TP to $87, Rating Reiterated at Buy3
DiAKESO Leaps 12%+; 2 Blockbuster Bi-specific Antibodies Expected to Cover 2K Hospitals This Yr4
SoAkeso, Inc.: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies60Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline...
► Artikel lesen
25.03.Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/AKESO13
21.03.Akeso, Inc.: Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting92HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at...
► Artikel lesen
19.03.AKESO (09926): DATE OF BOARD MEETING2
17.03.Akeso's Penpulimab Gets NMPA Approval For First-Line Treatment Of Nasopharyngeal Cancer-
07.03.Akeso, Inc.: Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet81HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase...
► Artikel lesen
06.03.Akeso, Inc.: Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma65HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its...
► Artikel lesen
27.02.Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy106HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the...
► Artikel lesen
25.02.Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings476NEW YORK CITY (dpa-AFX) - Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial collaboration with Pfizer Inc. (PFE)....
► Artikel lesen
25.02.Akeso, Inc.: Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs176HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics...
► Artikel lesen
21.02.Akeso, Inc.: Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer87HONG KONG, Feb. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient...
► Artikel lesen
13.02.Akeso, Inc.: Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC75HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in...
► Artikel lesen
06.02.Akeso, Inc.: Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC85HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the...
► Artikel lesen
23.01.Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine257HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature...
► Artikel lesen
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3